Overview

WP4 provides the economic evidence needed to justify large-scale investment in pharmacogenomics. We assess health benefits and develop economic model frameworks for the NHS.

Key Objectives

• Economic Modeling: Developing frameworks to value the implementation of genomic infrastructure.
• Stakeholder Consultation: Identifying key attributes for investment in line with HM Treasury’s Green Book.
• Sustainability: Assessing the long-term impact of reducing the annual cost of ADRs to the healthcare system.

Featured Resources

• UK Launches CERSI-PGx to Revolutionise Pharmacogenomics and Patient Safety

Leads